Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder

Sponsor
Neuronetics (Other)
Overall Status
Completed
CT.gov ID
NCT01415154
Collaborator
(none)
67
Enrollment
6
Locations
2
Arms
35
Duration (Months)
11.2
Patients Per Site
0.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the efficacy of scheduled maintenance Transcranial Magnetic Stimulation (TMS) treatment compared to on-demand TMS treatment for symptomatic worsening in patients who have shown a clinical response to acute TMS treatment.

Condition or DiseaseIntervention/TreatmentPhase
  • Device: NeuroStar TMS
N/A

Detailed Description

This is a 12-month maintenance treatment study for patients who have responded to a 6 week course of acute TMS treatment for major depressive disorder (MDD). The study will seek to assess the change in depressive symptomatology across the duration of maintenance treatment using observer and self-administered efficacy measures. Describe the efficacy of TMS re-introduction in patients not receiving maintenance pharmacotherapy who show a recurrence of depressive symptoms. Assess the safety and durability of acute TMS therapy followed by maintenance TMS treatment for up to 12 months.

Study Design

Study Type:
Interventional
Actual Enrollment :
67 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A 12-Month Prospective Randomized Dual-Arm Pilot Study of Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder
Study Start Date :
Aug 1, 2011
Actual Primary Completion Date :
Sep 1, 2013
Actual Study Completion Date :
Jul 1, 2014

Arms and Interventions

ArmIntervention/Treatment
Experimental: Scheduled Treatment Arm

3 Week TMS taper, clinical assessments and one NeuroStar TMS session every 4th week of block and TMS reintroduction as needed for clinical deterioration.

Device: NeuroStar TMS
NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.

Experimental: Monthly Observational Follow up Arm

3 Week TMS Taper, clinical assessments and office follow up every 4th week of block and NeuroStar TMS reintroduction as needed for clinical deterioration.

Device: NeuroStar TMS
NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.

Outcome Measures

Primary Outcome Measures

  1. Examining the proportion of patients maintaining a sustained response throughout a 12 month maintenance treatment phase. [12 month evaluation]

    Sustained response is defined as not requiring TMS reintroduction at every observation point during the maintenance phase.

Secondary Outcome Measures

  1. Compare the average time to first reintroduction of TMS between the two maintenance treatment arms. [12 Month evaluation]

    Change in depressive symptomatology will be assessed across the duration of maintenance treatment using observer and self-administered efficacy measures.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Primary diagnosis by DSM-IV criteria for Major Depressive Episode, single episode or recurrent course of illness, with the additional stipulation of a duration for this episode of ≥ 4 weeks and CGI-S ≥ 4.

  • Duration of current episode of depression ≤ 3 years (the definition of an episode is demarcated by a period of ≥ 2 months when the patient did not meet full criteria for the DSM-IV definition of Major Depressive Episode.

  • Capable and willing to provide informed consent.

  • Signed HIPAA authorization.

  • Able to adhere with the treatment schedule, and withdrawal of ongoing pharmacotherapy.

  • If currently taking antidepressant pharmacotherapy, must be clinically appropriate to discontinue treatment with those agents.

Exclusion Criteria:
  • Investigators, site personnel directly affiliated with this study, and their immediate families (immediate family is defined as a spouse, parent, child or sibling, whether by birth or legal adoption).

  • Individuals diagnosed by the Investigator with the following conditions (current unless otherwise stated):

  • Depression secondary to a general medical condition, or substance- induced;

  • Seasonal pattern of depression as defined by DSM-IV;

  • History of substance abuse or dependence within the past year except nicotine and caffeine);

  • Any psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features in this or previous episodes;

  • Bipolar disorder;

  • Eating disorder (current or within the past year);

  • Obsessive compulsive disorder (lifetime); or

  • Post-traumatic stress disorder (current or within the past year).

  • An Axis II Personality Disorder, which in the judgment of the Investigator may hinder the patient in completing the procedures required by the study protocol.

  • Individuals with a clinically defined neurological disorder or insult including, but not limited to:

  • Any condition likely to be associated with increased intracranial pressure;

  • Space occupying brain lesion;

  • History of cerebrovascular accident;

  • Transient ischemic attack within two years;

  • Cerebral aneurysm;

  • Dementia;

  • Parkinson's disease;

  • Huntington's chorea;

  • Multiple sclerosis.

  • Increased risk of seizure for any reason, including but not limited to prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or history of significant head trauma with loss of consciousness for ≥ 5 minutes.

  • History of treatment with Vagus Nerve Stimulation.

  • Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease.

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1Rush University Medical CenterChicagoIllinoisUnited States60612
2Sheppard Pratt Health SystemBaltimoreMarylandUnited States21285
3Premier Psychiatric Group, L.L.C.LincolnNebraskaUnited States68526
4Butler HospitalProvidenceRhode IslandUnited States02906
5Medical University of South CarolinaCharlestonSouth CarolinaUnited States29425
6Center for Anxiety and DepressionMercer IslandWashingtonUnited States98040

Sponsors and Collaborators

  • Neuronetics

Investigators

  • Study Director: David G. Brock, MD, Neuronetics

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Neuronetics
ClinicalTrials.gov Identifier:
NCT01415154
Other Study ID Numbers:
  • 44-03001-000
First Posted:
Aug 11, 2011
Last Update Posted:
Oct 8, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Neuronetics
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 8, 2021